ONFAB

ONFAB, headquartered in the United Kingdom, stands as a prominent player in the pharmaceutical industry's niche segment of flexible containment solutions. Established in 2004, the company has carved a significant partnership space, collaborating with global pharmaceutical giants like Pfizer, AstraZeneca, and Sanofi to manage and contain processes involving High Potent Active Pharmaceutical Ingredients (HPAPIs).

Under the umbrella of Savillex, and with a recent acquisition investment concluded on 01 November 2023, ONFAB benefits from robust backing, positioning it to leverage its extensive industry experience to optimize manufacturing processes. The company is recognized for its exceptional standards as evidenced by its ISO 9001 accreditation, ensuring high-quality management practices.

In summary, ONFAB represents a mature yet dynamic venture with significant incumbency in the pharmaceutical containment space, bolstered by strategic partnerships and a commitment to quality, making it an appealing prospect for investors looking at the intersection of pharmaceuticals and manufacturing innovations.